ticagrelor / Generic mfg. - LARVOL DELTA

Ticagrelor vs. Clopidogrel in ACS Patients Underwent PCI: An Analysis Based on Systemic Immune-inflammation Risk Stratification. (PubMed, Thromb Haemost) - "In the high-SII group (1,299 matched pairs), ticagrelor was associated with reduced ischemic events (HR 0.52; 95% CI: 0.33-0.83; p = 0.006), cardiac death (HR 0.45; 95% CI: 0.23-0.86; p = 0.015), and all-cause mortality (HR 0.40; 95% CI: 0.23-0.70; p = 0.001) without association with increased major bleeding. The SII is associated with 12-month post-PCI ischemic and mortality risk and demonstrates potential as a candidate biomarker for risk stratification, with exploratory observations of ticagrelor benefit in high-SII and clopidogrel adequacy in low-SII patients."

Journal • Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease • Inflammation • Myocardial Infarction

Gastrointestinal Bleeding Risk With Ibrutinib Versus Second Generation BTK Inhibitors in B-Cell Malignancies: A Large Real-World Cohort Analysis (ACG 2026) - "Newer second-generation BTK inhibitors are widely assumed to carry lower bleeding risk, but real-world comparative data on GI bleeding outcomes between first-generation (Ibrutinib) and second-generation BTK inhibitors (acalabrutinib, zanubrutinib) remains limited...Propensity score matching was performed on demographics, anticoagulant use, antiplatelets (aspirin, clopidogrel, ticagrelor), NSAIDs, thrombocytopenia, peptic ulcer disease, hemorrhoids, esophageal varices, liver disease, cirrhosis, and alcohol use... 3,653 patients per cohort were compared: composite GI hemorrhage (2.6% vs. 2.6%; RR 1.01, 95% CI 0.76-1.35; p=0.925; HR 1.04, p=0.663), melena (2.6% vs. 3.0%; p=0.333) and anorectal hemorrhage (1.5% vs."

Clinical • Real-world • Real-world evidence • Chronic Lymphocytic Leukemia • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Hepatology • Immunology • Lymphoma • Lymphoplasmacytic Lymphoma • Mantle Cell Lymphoma • Oncology • Peptic Ulcer • Thrombocytopenia • Waldenstrom Macroglobulinemia

Dual antithrombotic therapy with dabigatran and ticagrelor in patients with acute coronary syndrome and non-valvular atrial fibrillation undergoing percutaneous coronary intervention (ADONIS-PCI): protocol for a randomized controlled pilot trial. (PubMed, Cardiol J) - P4 | "ADONIS-PCI is among the first randomized evaluations of a reduced-dose long-term ticagrelor strategy combined with dabigatran in patients with AF and ACS undergoing PCI. The trial addresses an important evidence gap in the selection and dosing of P2Y12 inhibition when aspirin is discontinued early in this high-risk population."

Clinical protocol • Journal • Acute Coronary Syndrome • Atrial Fibrillation • Cardiovascular • Hematological Disorders • Myocardial Infarction

Opioid Analgesia in Acute Myocardial Infarction: Pharmacokinetic Interaction with P2Y12 Inhibitors and Pharmacodynamic Consequences-A Clinical Review for Emergency Physicians. (PubMed, J Emerg Med) - "In practice, pain relief should proceed alongside diagnosis and reperfusion. Nitroglycerin is appropriate when hemodynamics allow; an opioid is reasonable for severe pain that persists despite tolerated anti-ischemic therapy or when nitrates cannot be used. Small titrated doses, reassessment before redosing, and clear communication of opioid exposure, vomiting, shock, and P2Y12 loading time are more defensible than routine administration."

Journal • PK/PD data • Cardiovascular • Hematological Disorders • Myocardial Infarction • Pain • Thrombosis

Probabilistic Risk-Benefit Profile of Ticagrelor Monotherapy After Short Dual Antiplatelet Therapy: A Bayesian Analysis of the ULTIMATE-DAPT Trial. (PubMed, Clin Pharmacol Ther) - "In mixed cohorts including chronic coronary syndrome patients, probabilities of increased stent thrombosis rose to 75.8%-87.7% and myocardial infarction exceeded 91.0%, particularly with aspirin withdrawal at ≤ 1 month. These findings provide complementary quantitative, population-level evidence indicating that ticagrelor monotherapy after short DAPT was associated with reduced bleeding and a low posterior probability of increased overall ischemic risk, although potential ischemic risks remained with very early aspirin withdrawal and in mixed cohorts including chronic coronary syndrome patients."

Benefit-risk assessment • Journal • Monotherapy • Cardiovascular • Hematological Disorders • Myocardial Infarction • Thrombosis

Temporal Trends and Predictors of P2Y12 Inhibitor Selection and Switching Following Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients. (PubMed, Am J Cardiovasc Drugs) - "In this real-world cohort of patients with ACS undergoing PCI, initial P2Y12 inhibitor selection varied by demographic, clinical, procedural, and geographic characteristics. Recorded ticagrelor-to-clopidogrel switching was common but should not be interpreted uniformly as intentional clinical de-escalation. These findings highlight the need for future research to clarify reasons for switching and to inform individualized P2Y12 inhibitor treatment strategies in routine practice."

Journal • Acute Coronary Syndrome • Cardiovascular • Myocardial Infarction

Hemoadsorption in Patients Receiving Ticagrelor or Factor Xa Inhibitors (KIDNEY WEEK 2026) - No abstract available

Clinical

Impact of antiplatelet therapy on erectile dysfunction following percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. (PubMed, Front Med (Lausanne)) - "In male patients with STEMI, moderate-to-severe ED and bleeding episodes were common during DAPT. P2Y12 inhibitor type (ticagrelor vs. clopidogrel) and bleeding episodes were associated with moderate-to-severe ED."

Journal • Cardiovascular • Erectile Dysfunction • Myocardial Infarction • Pulmonary Disease

Prasugrel in the management of acute coronary syndromes: a systematic review. (PubMed, Daru) - "In eligible ACS patients proceeding to intervention, prasugrel is the preferred or co-preferred P2Y12 inhibitor in contemporary European and American guidelines. Platelet function testing-guided de-escalation to clopidogrel provides a validated alternative strategy for patients at elevated bleeding risk during the maintenance phase of therapy."

Journal • Review • Acute Coronary Syndrome • Cardiovascular

TICAdSORB: Ticagrelor Hemoadsorption Using Cytosorb® for Reduction of Bleeding During Cardiac Surgery (clinicaltrials.gov) - P=N/A | N=232 | Not yet recruiting | Sponsor: University Hospital, Rouen

New trial • Cardiovascular

VerifyNow in acute coronary syndrome: design of the EPIC17-VERONICA trial to optimize platelet inhibition. (PubMed, REC Interv Cardiol) - P4 | "De-escalation from prasugrel and ticagrelor to clopidogrel in patients undergoing percutaneous coronary intervention after acute coronary syndrome (ACS) is a strategy aimed at reducing bleeding. The EPIC17-VERONICA study (NCT04654052) will reveal the efficacy profile of the de-escalation strategy, based on the VerifyNow platelet aggregation test, and determine the role of this device in the selection of patients who are eligible to benefit from this strategy. This study will determine whether platelet function testing provide clinical benefit in the management of patients with ACS."

Journal • Acute Coronary Syndrome • Cardiovascular • Myocardial Infarction

STELAR: Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery Disease (clinicaltrials.gov) - P4 | N=1000 | Not yet recruiting | Sponsor: University of Messina | Trial completion date: Sep 2027 ➔ Sep 2028 | Trial primary completion date: Dec 2026 ➔ Dec 2027

Monotherapy • Trial completion date • Trial primary completion date • Cardiovascular • Coronary Artery Disease

TALISCHER-SAH: TicAgreLor Versus Placebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blinded Randomised Controlled Study (clinicaltrials.gov) - P3 | N=274 | Not yet recruiting | Sponsor: University Hospital, Toulouse

New P3 trial • Cardiovascular • Hematological Disorders • Subarachnoid Hemorrhage • Vascular Neurology

Ultrashort vs Standard-Duration Dual Antiplatelet Therapy in Acute Coronary Syndrome Patients Undergoing PCI: A Meta-Analysis. (PubMed, JACC Cardiovasc Interv) - "In patients with ACS undergoing PCI, ultrashort DAPT reduced bleeding without increasing ischemic events overall, although a signal of increased MACCE was observed in STEMI but not in NSTE-ACS. Bleeding reduction was greater in East Asians, while ≤1-week DAPT or clopidogrel/aspirin monotherapy may increase ischemic risk."

Clinical • Journal • Retrospective data • Review • Acute Coronary Syndrome • Cardiovascular • Myocardial Infarction

Does residual ADP reactivity within the therapeutic range predict intraoperative thromboembolic events during endovascular treatment of intracranial aneurysms? (PubMed, Neuroradiology) - "In this cohort of 196 patients with adequate preoperative platelet inhibition, residual ADP-induced platelet reactivity was not associated with the risk of intraoperative thromboembolic complications. These findings suggest that residual ADP reactivity within the therapeutic range has limited value for predicting intraoperative thromboembolic events."

Journal • Cardiovascular • Hematological Disorders • Subarachnoid Hemorrhage • Thrombosis • Vascular Neurology

VISTA: Drug-eluting Stenting Versus Medical Treatment for Extracranial Vertebral Artery Stenosis (clinicaltrials.gov) - P=N/A | N=472 | Recruiting | Sponsor: Xuanwu Hospital, Beijing | Trial primary completion date: Sep 2025 ➔ Nov 2027

Trial primary completion date • Cardiovascular • Ischemic stroke

Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization (clinicaltrials.gov) - P=N/A | N=514 | Active, not recruiting | Sponsor: Massachusetts General Hospital | N=130 ➔ 514

Enrollment change • Cardiovascular • Hematological Disorders • Peripheral Arterial Disease • Thrombosis

Comparative Safety and Efficacy of Dual Antiplatelet Therapy Regimens in Flow Diversion for Intracranial Aneurysms: a Systematic Review and Network Meta-Analysis. (PubMed, Clin Neuroradiol) - "Current FD-specific evidence is insufficient to establish superiority, inferiority, or equivalence among clopidogrel-, ticagrelor-, and prasugrel-based DAPT regimens across ischemic, hemorrhagic, functional, and survival outcomes. Because treatment allocation was non-random and alternative regimens were preferentially used in patients with suspected clopidogrel hyporesponsiveness, these findings should not be read as supporting a clopidogrel-first hierarchy; regimen selection is likely to remain guided by local pharmacogenetic testing, and cost considerations pending higher-quality comparative data."

Journal • Retrospective data • Review • Cardiovascular • Hematological Disorders • Vascular Neurology

STREAMLINE: Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months (clinicaltrials.gov) - P4 | N=8100 | Recruiting | Sponsor: Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Coronary Syndrome • Cardiovascular • Myocardial Infarction

Indobufen-based dual antiplatelet therapy after percutaneous coronary intervention: A systematic review and network meta-analysis. (PubMed, J Int Med Res) - "The significant between-strategy differences concerned others: aspirin plus ticagrelor showed higher major bleeding (2.07, 1.46-2.94) and clopidogrel monotherapy lower (0.38, 0.22-0.64). Its relative position against other contemporary bleeding-reduction strategies remains unproven. These results reinforce the need for individualised antiplatelet therapy guided by patient-specific ischaemic and bleeding risk.INPLASY registration number: INPLASY202680037."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Hematological Disorders • Myocardial Infarction • Thrombosis

Low-dose ticagrelor combined with aspirin for preventing early neurological deterioration in patients with high-risk non-disabling ischemic cerebrovascular events: a multicenter, prospective, randomized, open-label, clinical trial. (PubMed, J Neurol) - P4 | "Among patients with HR‑NICE within 24 h of onset, low‑dose ticagrelor plus aspirin significantly decreased the incidence of END within 7 days and improved neurological functional outcomes at 90 days compared with clopidogrel plus aspirin, without increasing the risk of bleeding. This regimen may provide a safe and effective alternative antiplatelet strategy for END prevention in institutions lacking rapid genotyping facilities."

Clinical • Journal • Cardiovascular • CYP2C19

Clopidogrel versus Ticagrelor in Cocaine-Associated Acute Coronary Syndrome: A Propensity-Matched Real-World Analysis (AHA 2026) - "Abstract is embargoed at this time."

Clinical • Real-world • Real-world evidence • Acute Coronary Syndrome • Cardiovascular

Ticagrelor is Associated with Higher Major Adverse Cardiac Event Risk Than Clopidogrel in Kidney Transplant Recipients with Acute Coronary Syndrome: A TriNetX Retrospective Cohort Study (AHA 2026) - "Abstract is embargoed at this time."

Adverse events • Retrospective data • Acute Coronary Syndrome • Cardiovascular • Transplantation

Comparative Effectiveness and Safety of Prasugrel versus Ticagrelor After Percutaneous Coronary Intervention - A Real-World Cohort Study (AHA 2026) - "Abstract is embargoed at this time."

Clinical • HEOR • Real-world • Real-world evidence • Cardiovascular

Ticagrelor-Aspirin With Thrombolysis by Infarct Patterns in Moderate Ischemic Stroke: TAPIS Subgroup Analysis. (PubMed, Stroke) - P3 | "Early neurological improvement showed significant heterogeneity by infarction pattern (Pinteraction=0.02); the treatment‑by‑pattern interaction for the primary outcome was nominally significant after adjusting for rescue tirofiban use (P=0.04). These hypothesis‑generating findings may inform future trials of diffusion‑weighted imaging infarction pattern as an imaging biomarker to guide antiplatelet therapy in early reperfusion. URL: https://www.clinicaltrials.gov; Unique identifier: NCT06316570."

Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke